Dupilumab is a fully human Ig4 monoclonal antibody directed against the interleukin-4 receptor subunit α (IL-4Rα) of IL-4 and IL-13 receptors, blocking the effects of both cytokines, which are involved in T2 inflammation and, therefore, also in Nasal Polyps. This evidence concerns the gene IL4R and Nasal polyposis.